Actelion announces first quarter 2010 financial results
(Thomson Reuters ONE) -
Actelion Pharmaceuticals Ltd / Actelion announces first quarter 2010 financial results processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement.
Total net revenues of CHF 501.7 million - Product sales of CHF 449.8 million, up
20 percent in local currencies - Non-GAAP EBIT of CHF 197.8 million - US launch
of improved formulation of Epoprostenol for Injection
ALLSCHWIL/BASEL, SWITZERLAND - 22 April 2010 - Actelion Ltd (SIX: ATLN) today
announced financial results for the first quarter 2010.
+----------------------+---------------+---------------+----------+----------+
|In CHF Thousands |Results Q1 2010|Results Q1 2009|% Variance|% Variance|
| | | | In CHF | In LC |
+----------------------+---------------+---------------+----------+----------+
|Net Revenues | 501,663| 405,613| 24%| 28%|
+----------------------+---------------+---------------+----------+----------+
|Non-GAAP OPEX | 303,896| 259,074| 17%| 19%|
+----------------------+---------------+---------------+----------+----------+
|Non-GAAP EBIT | 197,767| 146,539| 35%| 43%|
+----------------------+---------------+---------------+----------+----------+
|Diluted EPS - Non-GAAP| 1.38| 1.05| 31%| 39%|
+----------------------+---------------+---------------+----------+----------+
|Diluted EPS - US GAAP | 1.09| 0.83| 31%| 41%|
+----------------------+---------------+---------------+----------+----------+
As of 31 March 2010, Actelion had cash, cash equivalents and marketable
securities of CHF 1.2 billion. In addition, Actelion holds 10.3 million treasury
shares.
In the first quarter of 2010 Actelion continued its growth trajectory, driven
yet again by strong demand for its medicines. These results support previously
announced 2010 guidance of more than 10 percent net revenue growth (in local
currencies) and non-GAAP EBIT growth close to 20 percent (in local currencies).
On 22 April 2010, Epoprostenol for Injection, an improved formulation of
epoprostenol that is stable at room temperature, has become available for the
treatment of primary pulmonary hypertension and pulmonary hypertension
associated with scleroderma spectrum of disease in NYHA Class III and Class IV
patients who do not respond adequately to conventional therapy. The introduction
of this product demonstrates Actelion's ongoing commitment to the pulmonary
arterial hypertension (PAH) community. It also expands Actelion's product
portfolio to four marketed medicines.
Actelion's leading role in the treatment of PAH is further evidenced by two
late-stage development candidates - macitentan, a highly potent,
tissue-targeting endothelin receptor antagonist and selexipag (proposed INN), a
first-in-class, orally active non-prostanoid, selective IP receptor agonist.
At the end of March 2010 Actelion had a total of 11 different molecules in
clinical development. In addition to macitentan and selexipag, Actelion is also
conducting Phase III programs of clazosentan in non-traumatic aneurismal
subarachnoid hemorrhage (aSAH) and almorexant in sleep disorders.
Jean Paul Clozel, M.D. and Chief Executive Officer of Actelion commented: "I am
very pleased with our performance this quarter, including the robust demand for
our products and our strong financial performance. This ongoing strong demand
for our medicines positions us well for the future, and allows us to make
appropriate investments in a wide range of innovative development candidates.
The introduction of new products, like the improved epoprostenol formulation,
will also enable us to further leverage our global infrastructure."
Revenue performance
Product sales for the first quarter of 2010 were CHF 449.8 million (Q1 2009 CHF
389.4 million, an increase of 20 percent in local currencies) with 43 percent
coming from the United States, 42 percent coming from Europe and 15 percent from
the rest of the world. Product sales growth was mostly driven by patient demand.
Sales of Tracleer® (bosentan) were CHF 405.2 million for the first quarter of
2010, compared to CHF 352.2 million for the same period in 2009, representing a
19 percent increase in local currencies.
During the first quarter of 2010, Ventavis® (iloprost) had sales in the United
States of CHF 27.7 million compared to CHF 27.0 million in the first quarter of
2009, representing an 11 percent increase in local currencies.
Sales of Zavesca® (miglustat) for the first quarter of 2010 were CHF 16.9
million, compared to CHF 10.3 million during the same period last year,
representing a 69 percent increase in local currencies.
Contract revenues for the first quarter 2010 were CHF 51.9 million compared to
CHF 16.2 million in the first quarter of 2009. The increase was primarily driven
by the accelerated recognition of Roche S1P1 milestones that will come to an end
in Q2 2010.
Operating expenses
Total operating expenses for the first quarter of 2010 were CHF 338.4 million
compared to CHF 284.0 million for the same period in 2009, an increase of 19
percent. The increase was driven by both, ongoing investments into R&D as well
as ongoing investments to further expand the use of our marketed products.
Research and Development (R&D) expenses in the first quarter of 2010 were CHF
116.1 million compared to CHF 95.8 million in the first quarter of 2009.
Non-GAAP R&D expenses for the first quarter of 2010, which excludes stock-based
compensation expense and amortization and depreciation, were CHF 104.4 million
compared to CHF 86.4 million in the first quarter of 2009.
Selling, General and Administrative expenses (SG&A) for the first quarter of
2010 were CHF 163.8 million compared to CHF 138.8 million in the first quarter
of 2009. Non-GAAP SG&A expenses for the first quarter of 2010, which excludes
stock-based compensation expense and amortization and depreciation, were CHF
151.7 million compared to CHF 129.7 million in the first quarter of 2009
Andrew J. Oakley, Chief Financial Officer of Actelion commented: "This is yet
another set of solid results demonstrating that Actelion is continuing to
operate from a strong base. I am confident that we will meet our guidance for
2010. Our strong balance sheet also enables us to continue the evaluation of
external growth opportunities."
Corporate updates
* On March 1, 2010 Actelion announced initial results of BUILD-3, a clinical
study evaluating the safety and efficacy of bosentan in patients suffering
from idiopathic pulmonary fibrosis (IPF). Whilst there was a consistent
trend in favor of bosentan, the primary endpoint, reduction in
morbidity/mortality, was not met (p=0.21). Following completion of full data
analysis, BUILD-3 findings will be presented at the upcoming American
Thoracic Society (ATS) Annual Meeting and in peer-reviewed publications.
* On March 9, 2010 Actelion announced that the company had received a complete
response letter from the U.S. Food and Drug Administration (FDA) for its
supplemental New Drug Application for Zavesca® for the treatment of
progressive neurological manifestations in adult and pediatric patients with
Niemann-Pick type C (NP-C) disease, a rare, neurodegenerative genetic
disorder. The FDA has requested additional preclinical and clinical
information and Actelion will work diligently with the FDA to explore the
best ways to address the points raised by the agency.
* On 22 April 2010, Epoprostenol for Injection, an improved formulation of
epoprostenol that is stable at room temperature, has become available in the
US. This formulation is indicated for the treatment of primary pulmonary
hypertension and pulmonary hypertension associated with scleroderma spectrum
of disease in NYHA Class III and Class IV patients who do not respond
adequately to conventional therapy. Simultaneously, Actelion has launched
the PROSPECT registry, a multicenter, observational, US-based registry that
will provide additional clinical experience on patients being treated with
Epoprostenol for Injection.
* In the first quarter, Actelion initiated the EPITOME clinical program that
will generate additional clinical experience data with Epoprostenol for
Injection. In early 2010, Actelion also commenced the process to obtain
regulatory approval in markets outside the U.S., beginning with a filing in
France.
Upcoming events
* Annual General Meeting of shareholders on 4 May 2010 in Basel (Congress
Centre 14.00).
* Efficacy, safety and tolerability results from the Phase IIa study of
selexipag in PAH will be presented by Prof. G. Simonneau MD, PhD, Clamart,
France at the American Thoracic Society (ATS) congress in New Orleans in the
morning of Monday 17 May 2010, Central Time (US).
* Actelion to host a PAH product and franchise overview during a
company-sponsored investor reception in New Orleans on Monday, 17 May
2010, 6pm Central Time (US).
* Actelion to report H1 financial results on 20 July 2010, at which point in
time the company will provide a comprehensive clinical pipeline update and
issue its 2010 half year report.
* Actelion to report, in October 2010, the results from CONSCIOUS-2, a Phase
III study evaluating the clinical benefits of clazosentan on
vasospasm-related morbidity and all-cause mortality post aneurysmal
subarachnoid hemorrhage. This study is expected to complete enrollment, with
close to 1,150 patients, at the end of April 2010.
###
Notes to the editor:
Actelion Ltd.
Actelion Ltd is a biopharmaceutical company with its corporate headquarters in
Allschwil/Basel, Switzerland. Actelion's first drug Tracleer®, an orally
available dual endothelin receptor antagonist, has been approved as a therapy
for pulmonary arterial hypertension. Actelion markets Tracleer® through its own
subsidiaries in key markets worldwide, including the United States (based in
South San Francisco), the European Union, Japan, Canada, Australia and
Switzerland. Actelion, founded in late 1997, is a leading player in innovative
science related to the endothelium - the single layer of cells separating every
blood vessel from the blood stream. Actelion's over 2,300 employees focus on
the discovery, development and marketing of innovative drugs for significant
unmet medical needs. Actelion shares are traded on the SIX Swiss Exchange
(ticker symbol: ATLN).
Conference Call Information
An investor conference call & webcast will be held at 14.00 hrs, CEST to discuss
the results. Please note this is a new time as a response to your feedback.
Date/Time:
22 April 2010 14.00 hrs - 15.00 hrs Basel (CET)
13.00 hrs - 14.00 hrs UK (GMT)
08.00 a.m. - 09.00 a.m. US (EST)
Conference Call Connect #:
Dial-in participants should start calling the number below 10-15 minutes before
the conference is due to start.
Dial: Europe: +41 (0)44 580 64 03
UK: +44 (0)203 147 47 52
US: +1 866 9311 573
Participant's mode:
Listen-Only with possibility to open individual lines during Q&A session.
Participants will be asked for their Name and Company.
Webcast Access:
Webcast participants should visit the Actelion websitehttp://www.actelion.com/
10-15 minutes before the conference is due to start. If you experience any
access problems go directly to the URL:
http://gaia.world-television.com/actelion/20100422/trunc
Participant's mode:
Listen-Only with possibility to ask individual questions by clicking on the Q&A
button.
Participants will be asked to provide their Name and Company.
Webcast Replay:
The archived Investor Webcast will be available for replay
throughhttp://www.actelion.com
approximately 60 minutes after the call has ended.
For further information please contact:
Roland Haefeli
Vice President, Head of Investor Relations & Public Affairs
Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, CH-4123 Allschwil
+41 61 565 62 62
+1 650 624 69 36
www.actelion.com
Full Financial Statement:
The full financial statement for the first quarter of 2010 can be found as a PDF
attached to the media release.
[HUG#1406561]
--- End of Message ---
Actelion Pharmaceuticals Ltd
Gewerbestrasse 16 Allschwil Switzerland
Financial Fact Sheet: http://hugin.info/131801/R/1406561/360042.pdf
Press Release PDF: http://hugin.info/131801/R/1406561/360040.pdf
Webcast: http://gaia.world-television.com/actelion/20100422/trunc
Unternehmensinformation / Kurzprofil:
Datum: 22.04.2010 - 07:00 Uhr
Sprache: Deutsch
News-ID 19467
Anzahl Zeichen: 0
contact information:
Town:
Allschwil
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 1322 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Actelion announces first quarter 2010 financial results"
steht unter der journalistisch-redaktionellen Verantwortung von
Actelion Pharmaceuticals Ltd (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
